Rosenthal M A, Raghavan D, Stuart-Harris R, Ackland S, Grygiel J
Department of Medical Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
Aust N Z J Surg. 1992 Nov;62(11):871-3. doi: 10.1111/j.1445-2197.1992.tb06942.x.
Forty-three patients with disseminated prostate cancer, resistant to orchidectomy or hormone therapy with estramustine were treated. Of the 33 evaluable patients, three patients had stable disease and two had a partial tumour response according to National Prostatic Cancer Project criteria. Twenty-five patients (58%) showed improvement in pain and urinary symptoms. Ten patients (23%) had side effects requiring cessation of therapy. These results show that estramustine has a limited role in the treatment of advanced prostate cancer and that therapy is frequently associated with intolerable side effects.
